Beta
260018

Combined Sofosbuvir/Daclatasvir and Chemotherapy Markedly Improve The Outcome of B-Lymphoid Malignancies in Patients with Both HCV Infection and B-Lymphoid Malignancy

Article

Last updated: 03 Jan 2025

Subjects

-

Tags

-

Abstract

Background: A high prevalence of hepatitis C virus (HCV) seropositivity is found in patients with B-cell lymphoproliferative disorders. Many studies show improvement of lymphoid malignancies outcome with the use of anti HCV treatment in patients with HCV infection and lymphoid malignancies especially indolent B cell lymphoma. Objective: This study aimed to examine the hypothesis if sofosbuvir based direct-acting antivirals (DAAs) combination could improve the outcome of patients with B cell lymphoid malignancies and HCV infection.
Patient and Methods: During the period from January 2017 to December 2019 all eligible patients diagnosed with B- lymphoid malignancies presented at Sohag University Hospital and Sohag Cancer Institute were included in the study. HCV positive patients were randomized to receive sofosbuvir based DAAs combination either concomitant with or after the end of chemotherapy.
Results: Patients with HCV infection are more likely to have advanced stage disease (stage 3/4), extra-nodal presentation, liver and BM infiltration. Disease free survival (DFS) and overall survival (OS) were better in the group that received sofosbuvir DAAs combination after the end of chemotherapy treatment compared to the other groups (P = 0.000, 0.000 respectively) and was not different between patients who received sofosbuvir based combination concomitant with chemotherapy and HCV negative B-lymphoid malignancies.
Conclusion: Sofosbuvir based DAAs combination improve the outcome of different types of lymphoid malignancies (DFS, OS) in patients with HCV infection associated lymphoid malignancies especially when given after the end of chemotherapy.

DOI

10.21608/ejhm.2022.260018

Keywords

HCV, B-lymphoid malignancies, Sofosbuvir, Daclatasvir, DAAs

Authors

First Name

walaa

Last Name

soliman

MiddleName

gamal

Affiliation

medical oncology, faculty of medicine, Sohag university, Sohag, Egypt.

Email

walaasoliman700@yahoo.com

City

sohag

Orcid

0000-0001-5624-0503

First Name

Amr Mohamed

Last Name

Zaghloul

MiddleName

-

Affiliation

-

Email

-

City

-

Orcid

-

First Name

Ali Mohammed

Last Name

Ali

MiddleName

-

Affiliation

-

Email

-

City

-

Orcid

-

First Name

Mohamed Soliman

Last Name

Gaber

MiddleName

-

Affiliation

-

Email

-

City

-

Orcid

-

Volume

89

Article Issue

1

Related Issue

36332

Issue Date

2022-10-01

Receive Date

2022-09-17

Publish Date

2022-10-01

Page Start

4,676

Page End

4,684

Print ISSN

1687-2002

Online ISSN

2090-7125

Link

https://ejhm.journals.ekb.eg/article_260018.html

Detail API

https://ejhm.journals.ekb.eg/service?article_code=260018

Order

86

Type

Original Article

Type Code

606

Publication Type

Journal

Publication Title

The Egyptian Journal of Hospital Medicine

Publication Link

https://ejhm.journals.ekb.eg/

MainTitle

Combined Sofosbuvir/Daclatasvir and Chemotherapy Markedly Improve The Outcome of B-Lymphoid Malignancies in Patients with Both HCV Infection and B-Lymphoid Malignancy

Details

Type

Article

Created At

22 Jan 2023